NCT04873869View on ClinicalTrials.gov

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

March 17, 2023

Study Completion Date

March 17, 2023

Conditions
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Interventions
DRUG

NBI-921352

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (4)

14642

University of Rochester, Rochester

20010

Children's National Hospital, Washington D.C.

76104

Cook Children's Medical Center, Fort Worth

94158

UCSF Medical Center, San Francisco

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY